Lenalidomide and pomalidomide increase both NKG2D ligand MICA and DNAM-1 ligand PVR membrane expression on human MM cell lines and primary malignant PCs, thus enhancing their susceptibility to NK cell recognition and killing [55]. The gene discussed is KLRK1; the disease is Miyoshi myopathy.